Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) EBT Margin (2016 - 2025)

Historic EBT Margin for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to 1236.67%.

  • Guided Therapeutics' EBT Margin changed N/A to 1236.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 1478.65%, marking a year-over-year increase of 41818700.0%. This contributed to the annual value of 34528.57% for FY2024, which is 309683700.0% down from last year.
  • Guided Therapeutics' EBT Margin amounted to 1236.67% in Q3 2025.
  • Guided Therapeutics' 5-year EBT Margin high stood at 357.89% for Q3 2021, and its period low was 65200.0% during Q4 2024.
  • Moreover, its 5-year median value for EBT Margin was 3950.0% (2023), whereas its average is 15384.63%.
  • As far as peak fluctuations go, Guided Therapeutics' EBT Margin surged by 331800000bps in 2022, and later crashed by -639937500bps in 2024.
  • Guided Therapeutics' EBT Margin (Quarter) stood at 740.0% in 2021, then tumbled by -4864bps to 36733.33% in 2022, then surged by 97bps to 1206.25% in 2023, then tumbled by -5305bps to 65200.0% in 2024, then skyrocketed by 98bps to 1236.67% in 2025.
  • Its EBT Margin stands at 1236.67% for Q3 2025, versus 693.16% for Q2 2025 and 65200.0% for Q4 2024.